Rabbit Polyclonal TRAIL antibody. Suitable for sELISA and reacts with Recombinant fragment - Human samples. Cited in 14 publications. Immunogen corresponding to Recombinant Fragment Protein within Human TNFSF10 aa 100 to C-terminus.
Images
Publications
Filter by
- Bioorganic chemistry 127:1059262022Structure-activity relationships reveal a 2-furoyloxychalcone as a potent cytotoxic and apoptosis inducer for human U-937 and HL-60 leukaemia cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesHenoc Del Rosario,Ester Saavedra,Ignacio Brouard,Daniel González-Santana,Celina García,Elena Spínola-Lasso,Carlos Tabraue,José Quintana,Francisco EstévezPubMed 35717804
- International journal of molecular sciences 22:2021Apoptosis Pathways Triggered by a Potent Antiproliferative Hybrid Chalcone on Human Melanoma Cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesIrene Rodríguez,Ester Saavedra,Henoc Del Rosario,Juan Perdomo,José Quintana,Filippo Prencipe,Paola Oliva,Romeo Romagnoli,Francisco EstévezPubMed 34948260
- Journal of clinical medicine 10:2021Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo.Applications:Unspecified applicationReactive species:Unspecified reactive speciesDorothee Winterberg,Lennart Lenk,Maren Oßwald,Fotini Vogiatzi,Carina Lynn Gehlert,Fabian-Simon Frielitz,Katja Klausz,Thies Rösner,Thomas Valerius,Anna Trauzold,Matthias Peipp,Christian Kellner,Denis Martin SchewePubMed 34203833
- Cancer chemotherapy and pharmacology 88:289-3062021NCTR fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYan Wang,Qiong Lei,Cangjie Shen,Nan WangPubMed 33942150
- Science advances 7:2021Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYohei Kitamura,Nobuhiko Kanaya,Susana Moleirinho,Wanlu Du,Clemens Reinshagen,Nada Attia,Agnieszka Bronisz,Esther Revai Lechtich,Hikaru Sasaki,Joana Liliana Mora,Priscilla Kaliopi Brastianos,Jefferey L Falcone,Aldebaran M Hofer,Arnaldo Franco,Khalid ShahPubMed 33658202
- Signal transduction and targeted therapy 6:42021Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer.Applications:Unspecified applicationReactive species:Unspecified reactive speciesJing Chen et. al.PubMed 33414378
- Scientific reports 10:199972020Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy.Applications:Unspecified applicationReactive species:Unspecified reactive speciesJae Do Yoo,Sang Mun Bae,Junyoung Seo,In Seon Jeon,Sri Murugan Poongkavithai Vadevoo,Sang-Yeob Kim,In-San Kim,Byungheon Lee,Soyoun KimPubMed 33203916
- Immunity, inflammation and disease 9:144-1562020Secreted TRAIL gene-modified adipose-derived stem cells exhibited potent tumor-suppressive effect in hepatocellular carcinoma cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesZhuo Liu,Shaojie Li,Tiexiang Ma,Jian Zeng,Xin Zhou,Huanyu Li,Min Tang,Xiang Liu,Feng Li,Bin Jiang,Ming Zhao,Ying ChenPubMed 33156578
- Biochemistry 59:3856-38682020Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand.Applications:Unspecified applicationReactive species:Unspecified reactive speciesNagamani Vunnam,Sophia Szymonski,Petra Hirsova,Gregory J Gores,Jonathan N Sachs,Benjamin J HackelPubMed 32941010
- Biomaterials science 8:5317-53282020Biosilicified oncolytic adenovirus for cancer viral gene therapy.Applications:Unspecified applicationReactive species:Unspecified reactive speciesHao Kong et. al.PubMed 32779647
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
- Standard buffer
- Form
- Lyophilized
- Clonality
- Polyclonal
Immunogen
- Recombinant Fragment Protein within Human TNFSF10 aa 100 to C-terminus. The exact immunogen used to generate this antibody is proprietary information. Database link P50591
Reactivity data
Select an application| sELISA | |
|---|---|
| Human | Predicted |
| Recombinant fragment - Human | Tested |
sELISA
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes To detect TRAIL by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with ab12124 as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant TRAIL. |
PredictedPredicted
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info - | Notes - |
Associated Products
Select an associated product type
9 products for Alternative Product
Target data
Function
Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.
Alternative names
CD253, APO2L, TRAIL, TNFSF10, Tumor necrosis factor ligand superfamily member 10, Apo-2 ligand, TNF-related apoptosis-inducing ligand, Apo-2L, Protein TRAIL
Recommended products
Rabbit Polyclonal TRAIL antibody. Suitable for sELISA and reacts with Recombinant fragment - Human samples. Cited in 14 publications. Immunogen corresponding to Recombinant Fragment Protein within Human TNFSF10 aa 100 to C-terminus.
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
- Standard buffer
- Form
- Lyophilized
- Clonality
- Polyclonal
- Immunogen
- Recombinant Fragment Protein within Human TNFSF10 aa 100 to C-terminus. The exact immunogen used to generate this antibody is proprietary information. Database link P50591
- Purification technique
- Affinity purification Immunogen
- Reconstitution
- Reconstitute with 200µl of sterile water.
- Concentration
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage duration
- 1-2 weeks
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- -20°C
- Aliquoting information
- Upon delivery aliquot
Notes
Although some customers have been successful in IHC we no longer batch test in this application.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
TRAIL also known as TNF-related apoptosis-inducing ligand plays an important role in inducing apoptosis. This protein has a mass of around 32 kDa and is expressed across various tissues including immune cells. TRAIL interacts with specific receptors on the cell surface to initiate a signaling cascade that results in programmed cell death. It is an attractive therapeutic target because of its selective ability to induce apoptosis in cancer cells while sparing most normal cells.
- Biological function summary
TRAIL's function extends beyond inducing cell death. It is an important member of the tumor necrosis factor (TNF) superfamily which regulates immune responses and inflammation. TRAIL can form a homotrimeric complex allowing it to bind effectively to death receptors on target cells specifically DR4 and DR5 triggering a series of downstream signaling events. This interaction is significant in modulating immune surveillance and tumor suppression.
- Pathways
TRAIL is integral to both intrinsic and extrinsic apoptosis pathways. Through these pathways TRAIL is closely related to FADD and caspase-8 which are important for apoptosis induction. The extrinsic pathway involves binding to TRAIL death receptors leading to DISC formation while the intrinsic pathway involves mitochondrial events mediated by members of the Bcl-2 protein family.
- Associated diseases and disorders
TRAIL has a significant connection with cancer and autoimmune diseases. TRAIL plays a dual role in cancer where it acts as a tumor suppressor but can also promote tumor progression if cancer cells become resistant to its effects. In cancer TRAIL’s interaction with proteins like FLIP can alter the apoptotic potential of the cells. In autoimmune diseases TRAIL's dysregulation can contribute to tissue damage due to increased immune activity highlighting its complex role in maintaining immune balance.
Product promise
Tested
We have tested this species and application combination and it works. It is covered by our product promise.
Expected
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
Predicted
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
Not recommended
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Sandwich ELISA - Anti-TRAIL antibody (ab9959)
Standard curve for TRAIL (Analyte: Recombinant Human TRAIL protein ab78818); dilution range 1pg/ml to 1μg/ml using Capture Antibody Mouse monoclonal [55B709.3] to TRAIL (ab12124) at 0.2μg/ml and Detector Antibody Rabbit polyclonal to TRAIL (ab9959) at 0.1μg/ml.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com